Zai Lab Ltd
No SEC Form 4 filings for $ZLAB in the last 30 days.
See all $ZLAB insider activity →Zai Lab (NASDAQ:ZLAB) said it plans to seek China NRDL inclusion for VYVGART HYTRULO and shift the VYVGART franchise from IV to subcutaneous. Management flagged timing effects on second-half revenue, aims to stabilize revenue before stronger 2027 growth, and reported $717.5M cash. It outlined zoci ADC Phase III plans and pipeline updates.
Zai Lab Ltd (ZLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 zlab-202686x8kex991.htm EX-99.1 Document Exhibit 99.1 Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates – The Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with signifi
Du Ying (Chairperson & CEO) sold 7,026 shares of Zai Lab Ltd (ZLAB) at $18.53 ($0.13M total) on 2026-06-30.
Over the past 7 days, alphai's AI scored 2 news stories mentioning ZLAB (Zai Lab Ltd). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent ZLAB coverage spans financial news, earnings and insider activity.
Near-term commercial execution and multiple clinical/regulatory milestones could re-rate Zai Lab’s revenue trajectory and probability-weighted pipeline value.
The 8-K combines fresh financial datapoints with forward-looking clinical and regulatory milestones that can re-rate the probability-weighted pipeline value.
Routine insider open-market sale; likely limited incremental signal versus broader fundamentals.
Routine insider sale with no 10b5-1 plan disclosed; may slightly pressure sentiment but is not, by itself, a fundamental change.
This is a corporate governance/AGM voting update with no disclosed operational or financial change.
alphai scores every news story that mentions ZLAB with an AI model for sentiment and relevance, and aggregates insider trades from Zai Lab Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Zai Lab (NASDAQ:ZLAB) said it plans to seek China NRDL inclusion for VYVGART HYTRULO and shift the VYVGART franchise from IV to subcutaneous. Management flagged timing effects on second-half revenue, aims to stabilize revenue before stronger 2027 growth, and reported $717.5M cash. It outlined zoci ADC Phase III plans and pipeline updates.
7 min readZai Lab Ltd (ZLAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 zlab-202686x8kex991.htm EX-99.1 Document Exhibit 99.1 Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates – The Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with signifi
6 min readDu Ying (Chairperson & CEO) sold 7,026 shares of Zai Lab Ltd (ZLAB) at $18.53 ($0.13M total) on 2026-06-30.
1 min readDu Ying (Chairperson & CEO) sold 24,543 shares of Zai Lab Ltd (ZLAB) at $17.46 ($0.43M total) on 2026-06-26.
2 min readZai Lab Ltd (ZLAB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. zlab-20260617 false 0001704292 0001704292 2026-06-17 2026-06-17 0001704292 dei:AdrMember 2026-06-17 2026-06-17 0001704292 us-gaap:CommonStockMember 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ FORM 8-K ____
2 min readThe article discusses AI and robotics themes and promotes a newsletter tied to Zai Lab (ZLAB) leadership changes. It cites remarks from Amazon CEO Andy Jassy and Elon Musk’s 2040 humanoid-robot forecast, and references prior stock performance claims by Insider Monkey’s Inan Dogan. It provides no verifiable Zai Lab leadership details or financial figures.
6 min readHelix Biopharma (OTCMKTS:HBPCF) and Zai Lab (NASDAQ:ZLAB) are compared across profitability, risk, ownership, analyst views, and valuation. Zai Lab has 41.7% institutional ownership; Helix has 7.6% insider ownership. Zai Lab’s consensus target is $45.83 (MarketBeat), implying 148.82% upside. The article says Zai Lab leads on 10 of 14 factors.
4 min readZai Lab announced that Josh Smiley will cease serving as President and Chief Operating Officer, effective May 18, 2026. His responsibilities will be taken over by Samantha Du, the Board Chair, Founder, and CEO, along with other management members. Smiley is expected to receive severance pay according to his employment agreement.
2 min readYing Du has filed a Form 144 to sell blocks of American Depositary Shares (ADSs) of Zai Lab Ltd (ZLAB). The filing outlines multiple proposed dispositions throughout 2026, including several instances of 50,000 shares each with specified gross proceeds. This is a procedural notice for proposed sales by an affiliate and does not confirm actual transactions.
2 min readZai Lab (NasdaqGM:ZLAB) closed FY 2025 with Q4 revenue of US$127.6 million and a basic EPS loss of US$0.46, with trailing 12-month revenue at US$460.2 million and an EPS loss of US$1.60. Despite growing revenue, the company reported a net loss of US$175.5 million for the trailing 12 months, and current forecasts do not anticipate profitability within the next three years. This situation presents a classic growth versus profitability debate, with the stock trading at US$19.77 against a DCF fair value of US$80.05, raising questions about the sustainability of its losses at this scale.
4 min read
